Bat virome

CDC: Surface Disinfection Is "Hygiene Theater" -- PuraFil Shares Why Efforts Should Be Aimed at Mitigating Risk of Airborne COVID Transmission

Retrieved on: 
Tuesday, May 11, 2021
Coronaviridae, Sarbecovirus, Health, Medical specialties, Occupational safety and health, Zoonoses, Bat virome, Severe acute respiratory syndrome, COVID-19, Transmission of COVID-19, Science diplomacy and pandemics

According to the CDC\'s recently updated (April 5) guidance on COVID spread, "surface transmission is not the main route by which SARS-CoV-2 spreads, and the risk is considered to be low."

Key Points: 
  • According to the CDC\'s recently updated (April 5) guidance on COVID spread, "surface transmission is not the main route by which SARS-CoV-2 spreads, and the risk is considered to be low."
  • In fact, the CDC states "contact with a contaminated surface has less than a 1 in 10,000 chance of causing an infection.
  • "\nThose odds are just slightly higher than your lifetime risk of being struck by lightning ( 1 in 15,300 ).
  • Despite these low odds, many don\'t seem to be making major changes to their infection prevention protocols.

Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunological Response to SARS-CoV-2 Infection in Patients with Primary and Secondary Antibody Deficiency

Retrieved on: 
Tuesday, May 11, 2021
Sarbecovirus, Medical specialties, Respiratory diseases, Zoonoses, Bat virome, COVID-19, Occupational safety and health, Public health, Humoral immune deficiency, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Variants of SARS-CoV-2

The study will monitor the clinical course of SARS-CoV-2 infection and the immunological response of patients to vaccination.

Key Points: 
  • The study will monitor the clinical course of SARS-CoV-2 infection and the immunological response of patients to vaccination.
  • The study will collect samples from 13 sites around the UK.\nThe COV-AD study aims to build on the UK Primary Immunodeficiency Network (UKPIN) data by determining the prevalence, course and outcomes of SARS-CoV-2 infection in patients with Primary Antibody Deficiency (PAD)/Secondary Antibody Deficiency (SAD).
  • Development of anti-SARS-CoV-2 immunity to COVID infection or vaccination will be tested by blood sampling to measure specific antibody titre and for the presence of anti-SARS-CoV-2 T cells.
  • Our leading product, the T-SPOT.TB test, is used for diagnosing infection with Tuberculosis, the world\xe2\x80\x99s largest cause of death from infectious disease.

GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 6, 2021
Zoonoses, Sarbecovirus, Animal diseases, Veterinary medicine, Bat virome, Merbecovirus, Betacoronavirus, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, COVID-19

Details are provided further below.\nCapital Resources\xe2\x80\x93 On February 11, 2021, GeoVax supplemented its cash resources through a $10.3 million follow-on offering of common stock ($9.4 million net proceeds).

Key Points: 
  • Details are provided further below.\nCapital Resources\xe2\x80\x93 On February 11, 2021, GeoVax supplemented its cash resources through a $10.3 million follow-on offering of common stock ($9.4 million net proceeds).
  • SARS-CoV-2 is a type of coronavirus (a Betacoronavirus) that also causes Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
  • We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.
  • We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.\n'

Zero-Contact Medical Station for a Safe and Rapid PCR Covid-19 Testing

Retrieved on: 
Thursday, May 6, 2021
Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Infectious diseases, Medical specialties, Animal diseases

He adds that "Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff.

Key Points: 
  • He adds that "Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff.
  • This allows the medical staff to achieve nasal swabbing without patient contact and eliminates the need to wear a PPE.
  • Nasal Swab Robot just obtained the CE mark with Class I.\nThe Zero-Contact Medical Station achieves zero-contact swabbing and pipettingtasks for lab technicians.
  • To find out more about the Zero-Contact Medical Station, please visit our website https://brainnavi.com/zerocontactstation/ .\n'

Zero-Contact Medical Station for a Safe and Rapid PCR Covid-19 Testing

Retrieved on: 
Thursday, May 6, 2021
Bat virome, Sarbecovirus, Severe acute respiratory syndrome, COVID-19, Health, Animal diseases, Medical specialties

He adds that "Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff.

Key Points: 
  • He adds that "Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff.
  • This allows the medical staff to achieve nasal swabbing without patient contact and eliminates the need to wear a PPE.
  • Nasal Swab Robot just obtained the CE mark with Class I.\nThe Zero-Contact Medical Station achieves zero-contact swabbing and pipettingtasks for lab technicians.
  • To find out more about the Zero-Contact Medical Station, please visit our website https://brainnavi.com/zerocontactstation/ .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/zero-contact-medical-station-for...\nSOURCE Brain Navi Biotechnology Co., Ltd.\n'

NEC Contributes to Development of Artificial DNA Aptamer that Binds to the Novel Coronavirus (SARS-CoV-2)

Retrieved on: 
Thursday, May 6, 2021
Sarbecovirus, Zoonoses, Animal diseases, Bat virome, Veterinary medicine, Biotechnology, Nucleic acids, Aptamer, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome–related coronavirus, Coronavirus, Middle East respiratory syndrome–related coronavirus

b'TOKYO, May 6, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) and NEC Solution Innovators today announced the successful development of artificial DNA aptamers (1) that bind to the novel coronavirus (SARS-CoV-2).

Key Points: 
  • b'TOKYO, May 6, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) and NEC Solution Innovators today announced the successful development of artificial DNA aptamers (1) that bind to the novel coronavirus (SARS-CoV-2).
  • This aptamer uses a new modified base called Base appended Base ((5), Patent No.
  • In fiscal 2021, NEC expects to provide a prototype of a fixed-type spatial monitoring measuring device for companies, universities and other research institutions that perform virus measurement and other measures.
  • For more information, visit NEC at https://www.nec.com.\n'

Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Retrieved on: 
Monday, May 3, 2021
Sarbecovirus, Zoonoses, Bat virome, Medical specialties, Virology, Antiviral drugs, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome–related coronavirus, Coronavirus, 3C-like protease

\xe2\x80\x9cThese drug candidates bind to a highly conserved region of the active site of SARS-CoV-2 protease that is required for SARS-CoV-2 viral replication.

Key Points: 
  • \xe2\x80\x9cThese drug candidates bind to a highly conserved region of the active site of SARS-CoV-2 protease that is required for SARS-CoV-2 viral replication.
  • Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-2 infected mice.
  • In addition to these two SARS-CoV-2 protease programs, we are also developing novel SARS-CoV-2 inhibitors that block viral replication and transcription.
  • Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial

Retrieved on: 
Friday, April 30, 2021
Cytokines, Medical specialties, Branches of biology, Medicine, Antiviral drugs, Zoonoses, Bat virome, Interferon beta-1a, Interferon, COVID-19, Severe acute respiratory syndrome

A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells.

Key Points: 
  • A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells.
  • In parallel with the Phase III trial in the hospital setting, there is now an urgent need to assess SNG001 in the non-hospital setting, focussing entirely on breathless COVID-19 patients.
  • Please find a link to this webcast here.\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) No.
  • 596/2014 (\xe2\x80\x98MAR\xe2\x80\x99).\nThe Lancet Respiratory Medicine: "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial".

Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial

Retrieved on: 
Friday, April 30, 2021
Cytokines, Medical specialties, Branches of biology, Medicine, Antiviral drugs, Zoonoses, Bat virome, Interferon beta-1a, Interferon, COVID-19, Severe acute respiratory syndrome

A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells.

Key Points: 
  • A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells.
  • In parallel with the Phase III trial in the hospital setting, there is now an urgent need to assess SNG001 in the non-hospital setting, focussing entirely on breathless COVID-19 patients.
  • Please find a link to this webcast here.\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) No.
  • 596/2014 (\xe2\x80\x98MAR\xe2\x80\x99).\nThe Lancet Respiratory Medicine: "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial".

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups

Retrieved on: 
Thursday, April 29, 2021
Tuberculosis, Infectious diseases, Medical specialties, Respiratory diseases, Zoonoses, Bat virome, T-SPOT.TB, COVID-19, Severe acute respiratory syndrome, Tuberculosis diagnosis

Oxford Immunotec is collaborating with researchers at the University of Leicester on DIRECT (Determining the Immune Response in Ethnic minority healthcare workers to COVID-19 infection).

Key Points: 
  • Oxford Immunotec is collaborating with researchers at the University of Leicester on DIRECT (Determining the Immune Response in Ethnic minority healthcare workers to COVID-19 infection).
  • The study, funded through the National Core Studies group, is actively recruiting healthcare workers in Leicester for detailed analysis of their immune response to infection and / or vaccination (including T cells).
  • The T-SPOT Discovery SARS-CoV-2 test has also demonstrated in previous studies that a high SARS-CoV-2 specific T cell response may be associated with protection from infection.\nDr.
  • Our leading product, the T-SPOT.TB test, is used for diagnosing infection with Tuberculosis, the world\xe2\x80\x99s largest cause of death from infectious disease.